Results from two separate studies 419 and 564. Adapted from [76]. CR: Controlled release; IR: Immediate release.
![Figure 1. Mean plasma concentration–time curves at steady state for paroxetine IR 20 mg and paroxetine CR 25 mg.Results from two separate studies 419 and 564. Adapted from [76]. CR: Controlled release; IR: Immediate release.](/cms/asset/c9356ffa-ca31-48a0-885c-61329345f91a/iern_a_11213768_f0001_b.jpg)
IR: Immediate release. Adapted from [94].
![Figure 2. Likelihood of being compliant when compared with paroxetine controlled-release, controlling for age, gender, utilization of psychiatric specialty services, titration rates and the comorbidity measures.IR: Immediate release. Adapted from [94].](/cms/asset/1bbc169c-bcd2-448e-b602-199ecbb33dbe/iern_a_11213768_f0002_b.jpg)
Results from two separate studies 419 and 564. Adapted from [69]. CR: Controlled release; IR: Immediate release.
![Figure 1. Mean plasma concentration–time curves at steady state for paroxetine IR 20 mg and paroxetine CR 25 mg.Results from two separate studies 419 and 564. Adapted from [69]. CR: Controlled release; IR: Immediate release.](/cms/asset/c12d8f40-4630-4793-a3ec-2d3854f31749/iern_a_11213768_f0003_b.jpg)
IR: Immediate release. Adapted from [87].
![Figure 2. Likelihood of being compliant when compared with paroxetine controlled-release, controlling for age, gender, utilization of psychiatric specialty services, titration rates and the comorbidity measures.IR: Immediate release. Adapted from [87].](/cms/asset/324f9db2-72fe-4ea3-9d6c-d6f222e823e2/iern_a_11213768_f0004_b.jpg)
In the review by Chi-Un Pae and Ashwin A Patkar, Paroxetine: current status in psychiatry, published in the February 2007 issue of Expert Review of Neurotherapeutics (Expert Rev. Neurotherapeutics 7[2], 107–120 [2007]), the original text on page 111 reads:
GlaxoSmithKline’s recent letter to doctors points to a sixfold increase in the risk of suicidal behavior in adults taking paroxetine [104]; 32% (11 out of 3455) treated with paroxetine attempted suicide compared with 0.05% (one out of 1978) treated with placebo (OR: 6.7; 95% CI: 1.1–149.4).
The following figures on pages 112 and 115, respectively, show:
The corrected text should read:
GlaxoSmithKline’s recent letter to doctors points to a sixfold increase in the risk of suicidal behavior in adults taking paroxetine [104]; 0.32% (11 out of 3455) treated with paroxetine attempted suicide compared with 0.05% (one out of 1978) treated with placebo (OR: 6.7; 95% CI: 1.1–149.4).
The correct figures are given below:
The editors of Expert Review of Neurotherapeutics would like to sincerely apologize for any inconvenience or confusion the numbering error in this figure footnote may cause our readers.